CureVac starts Phase 1 trials for Omicron-specific vaccine - BioPharma-Reporter.com

CureVac has started the Phase 1 clinical study for its modified COVID-19 mRNA vaccine candidate CV0501: intended to be administered as a booster dose.

Developed in collaboration with GSK, CV0501 is based on CureVacs second-generation mRNA backbone and is designed to specifically protect against the Omicron variant. It is one of two second-generatio… [+1511 chars]

full article...